Showing 15 posts of 16 posts found.


China approves AstraZeneca’s heart failure drug Forxiga

February 4, 2021
AstraZeneca, Forxiga

AstraZeneca’s Forxiga (dapagliflozin) has been approved for use in China to reduce the risk of death and hospitalisation from heart …


Japan approves AstraZeneca’s Forxiga for chronic heart failure

November 30, 2020
Sales and Marketing AstraZeneca, Forxiga

Japan’s Ministry of Health, Labour and Welfare (MHLW) has announced the authorisation of AstraZeneca’s Forxiga as a treatment for chronic …


AZ’s diabetes drug Forxiga secures EU approval for adjunctive use in type 1 patients

March 25, 2019
Sales and Marketing AstraZeneca, Forxiga, diabetes, pharma

AstraZeneca has revealed that its sodium-glucose co-transporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin) has secured approval from the European Commission for …


AstraZeneca’s Forxiga displays potential in type 1 diabetes

September 14, 2017
Research and Development AstraZeneca, Forxiga, biotech, drugs, farxiga, pharma, pharmaceutical

Forxiga is AstraZeneca’s treatment for those living with type 2 diabetes but the results from a new trial have found …

NICE recommends Forxiga in Triple Therapy for Diabetes

October 7, 2016
Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes

The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …

Janssen Velcade

NICE recommends Velcade for MCL, and three diabetes drugs

December 23, 2015
Sales and Marketing Forxiga, NICE, Velcade, invokana, jardiance, mantel cell lymphoma, mcl

NICE has published final guidance recommending Velcade (bortezomib) as a treatment for previously untreated mantle cell lymphoma (MCL).  In the …


AstraZeneca scores positive real-world Forxiga data

September 16, 2015
Research and Development AstraZeneca, EASD, European Association for the Study of Diabetes, Forxiga, dapagliflozin, exenatide, real world data, real world evidence

The real-world study of AstraZeneca’s diabetes drug Forxiga has found its use in UK patients primary care patients supports the …

AZ image

AstraZeneca looks for revenue boost via Actavis buy

February 6, 2015
Sales and Marketing Actavis, AstraZeneca, Brilinta, Forxiga, diabetes, fourth quarter, q4

AstraZeneca recorded a dip in revenue in the last quarter of 2014 and is looking to ramp up its respiratory …

Astrazeneca image

AstraZeneca ‘simplifies decision-making’

February 4, 2014
Sales and Marketing AstraZeneca, BMS, Byetta, Forxiga, Onglyza, diabetes

AstraZeneca has completed its $4.3 billion acquisition of Bristol-Myers Squibb’s diabetes business, giving the company control over several big-name brands …

forxiga image

FDA approves Farxiga

January 10, 2014
Sales and Marketing AstraZeneca, BMS, FDA, Forxiga, diabetes

The FDA has approved Farxiga, the diabetes treatment developed by AstraZeneca and Bristol-Myers Squibb as part of their soon-to-be-defunct diabetes …

BMS image

BMS sells diabetes stake to partner AstraZeneca

December 19, 2013
Sales and Marketing AstraZeneca, BMS, Forxiga, Onglyza, diabetes, komboglyze

AstraZeneca will buy out Bristol-Myers Squibb’s stake in its diabetes alliance in a potential $4.3 billion deal. AZ will pay …

Forxiga image

AZ and BMS go for second Forxiga submission

July 29, 2013
Sales and Marketing AZ, BMS, FDA, Forxiga

AstraZeneca and partner Bristol-Myers Squibb have resubmitted their diabetes drug Forxiga to the FDA 18 months after it was rejected …

Forxiga image

NICE completes Forxiga U-turn

June 26, 2013
Sales and Marketing BMS, Forxiga, NICE

Bristol-Myers Squibb and AstraZeneca are celebrating after NICE reversed its decision from earlier this year and is now recommending their …

Forxiga image

NICE U-turn on Forxiga

May 30, 2013
Sales and Marketing Forxiga, NICE

NICE has recommended Bristol-Myers Squibb and AstraZeneca’s diabetes drug Forxiga in final draft guidance after turning its back on the …

Forxiga image

NICE rejects Forxiga

February 1, 2013
Sales and Marketing AstraZeneca, BMS, Forxiga, NICE, diabetes

NICE has given the thumbs-down to AstraZeneca and Bristol-Myers Squibb’s first-in-class type II diabetes treatment Forxiga. The drug was approved …

Latest content